AKT1 and asthma: There were evidences that selective PI3K inhibitors could reduce inflammation and some characteristics of diseases such as abnormal proliferation of airway smooth muscle cells (ASMC) in experimental animal models, which strongly supported that PI3K/Akt inhibitors might be a useful new therapy for asthma [37, 38].